Retina

Investigation evaluates safety of single and multiple intravitreal injections.

Understanding nuances of reimbursement for novel, sustained-release ophthalmic drugs can help maximize the opportunity for patients and practice.

Systemic immunosuppression may prevent devastating complication in patients.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

GT005 designed to induce local production of recombinant complement factor I.

Cotargeted therapy could help combat inherited retinal diseases.

Special to Ophthalmology Times®

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

Clinical trials show subretinal agents are safe, well tolerated by patients.

Option detects treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration

The study's finding suggest that the particles may be involved in some of the ocular clinical manifestations of the COVID-19 infection.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

Investigators have found that optical coherence tomography findings could prove to be a diagnostic tool for COVID-19.

Mitchell A. Jackson, MD, presents details of a retrospective review of dexamethasone intraocular suspension 9%, including reduced postoperative inflammation.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

This research was a finalist in the 2020 Ophthalmology Times® Research Scholar Honoree Program.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

Study highlights extracellular matrix-related proteins expressed in PVR.

Clues to diagnosis from patient/family histories, examination techniques.

Trial shows treatment has acceptable safety profile, may improve visual function.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

Novel treatments are now shifting paradigm in care of retinal diseases.

Retinal imaging tests are providing material to train and test decision-support systems.